TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosed with persistent asthma for 3 months or longer.~* Experienced worsened asthma symptoms during physical activity.~* Using an inhaled steroid for the previous 4 weeks or longer (such as Aerobid, Azmacort, Flovent, Pulmicort, QVAR, and Vanceril).~Exclusion criteria:~* Used systemic steroids as either liquids, pills, or injections to treat asthma within the previous 3 months.~* Have only intermittent, seasonal, or exercise-induced asthma, and not persistent asthma.~* Admitted to a hospital within the previous 6 months due to asthma symptoms.~* Any poorly controlled medical conditions that may make study participation unsafe or inappropriate in the opinion of the study physician (such as cystic fibrosis, congenital heart disease, insulin dependent diabetes, glaucoma, drug allergies, etc.)~* The study physician will evaluate other medical criteria.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- FSC 100/50 mcg BID (Type: EXPERIMENTAL): Participants received FSC 100/50 microgram (mcg) one inhalation as a combination product via DISKUS, twice daily in morning after awakening and in evening for up to 28 days
- FP 100 mcg BID (Type: EXPERIMENTAL): Participants received FP 100 mcg one inhalation via DISKUS, twice daily in morning after awakening and in evening for up to 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Normotensive male or female volunteers, with a body mass index of 18.0-30.0 kg/m2.~* Deemed healthy on the basis of a clinical history, physical examination, ECG, vital signs, and laboratory tests of blood and urine.~* Agree to follow the contraception requirements of the trial.~* Able to give fully informed written consent.~* Agree not to donate blood or blood products during the study and for up to 3 months after the administration of the trial medication.~Exclusion Criteria:~* History or presence of iron deficiency or iron deficiency anaemia and/or currently receiving oral or parenteral iron supplementation as treatment for those conditions.~* Positive tests for hepatitis B \& C, HIV~* Drug or alcohol abuse.~* Smoke more than 10 cigarettes (or equivalent) daily.~* Use of over-the-counter medication (with the exception of paracetamol \[acetaminophen\]) during the 7 days before the first dose of trial medication, or prescribed medication (with the exception of hormone replacement therapy \[HRT\]) during the 28 days before first dose of trial medication.~* Use of supplement(s) during the 28 days before screening.~* Participation in other clinical trials of unlicensed medicines, or loss of more than 400 mL blood, within the previous 3 months.~* Clinically relevant abnormal medical history or concurrent medical condition.~* Pre-menopausal females who are pregnant or lactating, or who are sexually active and not using a reliable method of contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 1.0mg/kg (Type: EXPERIMENTAL): Drug: SLN124
- Placebo (Type: PLACEBO_COMPARATOR): None
- 3.0mg/kg (Type: EXPERIMENTAL): Drug: SLN124
- Optional Cohort (Type: EXPERIMENTAL): An additional dose level may be explored

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Mild Hypothermia on Reversal of Rocuronium With Sugammadex

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient for elective abdominal surgery from 20 years (yrs) to 65 yrs Patient in American Society of Anesthesiologists criteria 1 or 2 Patient in the supine position with arm available for neuromuscular monitoring during operation~Exclusion Criteria:~* Patients expected to have a difficult airway, known neuromuscular disease, significant hepatic or renal dysfunction, family history of malignant hyperthermia, known allergy to one of the drugs used in this protocol, intake of any medication that might interact with muscle relaxants, pregnant, or breast feeding

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- C group (Type: ACTIVE_COMPARATOR): normal thermal condition with core temperatures between 36.5°C and 37°C
- H group (Type: EXPERIMENTAL): mild hypothermia with core temperatures between 34.5°C and 35°C

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Active rheumatoid arthritis (RA) diagnosed after the age of 16~* Currently taking methotrexate~* 6 or more swollen joints and 6 or more tender/painful joints (from 28 joint count) and either Erythrocyte Sedimentation Rate (ESR) blood result of 28mm/h or more, or C-Reactive Protein (CRP) blood result of 10mg/L or more~* At least one of the following: documented history of positive rheumatoid factor (blood test), current presence of rheumatoid factor (blood test), radiographic erosion within 12months prior to study enrolment, presence of serum anti-cyclic citrullinated peptide antibodies (blood test)~Exclusion Criteria:~* Females who are pregnant or breast feeding~* Poorly controlled hypertension~* Liver disease or significant liver function test abnormalities~* Certain inflammatory conditions (other than rheumatoid arthritis), connective tissue diseases or chronic pain disorders~* Recent or significant cardiovascular disease~* Significant active or recent infection including tuberculosis~* Previous failure to respond to anakinra or previous treatment with biological agent (other than TNF alpha antagonists including rituximab, abatacept and tocilizumab)~* Severe renal impairment~* Neutropenia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dosing Regimen A (Type: EXPERIMENTAL): Oral Treatment
- Dosing Regimen B (Type: EXPERIMENTAL): Oral Treatment
- Dosing Regimen C (Type: PLACEBO_COMPARATOR): Oral Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Completed the 6 month Treatment Period in pivotal study M12-665 (NCT01620528)~* Agrees to use required birth control methods during the study through Month 6 of the Post-treatment Follow-up period~Exclusion Criteria:~* Clinically significant gynecological condition~* Bone mineral density (BMD) loss greater than or equal to 8 percent in the spine, femoral neck or total hip~* Plans to become pregnant in the next 18 months

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Elagolix 150 mg QD (Type: EXPERIMENTAL): Participants received elagolix 150 mg tablets once a day (QD) for 6 months.
- Elagolix 200 mg BID (Type: EXPERIMENTAL): Participants received elagolix 200 mg tablets twice a day (BID) for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
1. Patients must have biopsy-proven locally-advanced, metastatic or recurrent adenocarcinoma of the biliary ducts or gallbladder.~2. Patients must have measurable disease.~3. Patients must be 18 years or older.~4. Patients must have a NCI CTC Performance Status of 0-2.~5. Patients must have a life expectancy of \>= 3 months.~6. Patients must not have any prior chemotherapy for metastatic disease. Prior adjuvant radiation therapy and chemotherapy with 5FU and/or gemcitabine is allowed.~7. At least 3 weeks should have elapsed since any surgery requiring general anesthesia.~8. Patients must have no prior malignancies except for basal or squamous skin cancers, cervical carcinoma-in-situ.~9. Pregnant patients are not eligible. Non-pregnant status will be determined in all women of childbearing potential. All patients will be required to use an effective means of contraception if sexually active during therapy.~10. Initial Required Laboratory Values:~    * 1. Absolute neutrophil count \>= 1,500/mm3, platelet count \>= 100,000/mm3, and hemoglobin \>= 9 g/dL.~   * 2. Serum creatinine should be \<= 2 mg/dL.~   * 3. Serum bilirubin should be \<= 3.0 mg/dL (biliary stents allowed).~   * 4. Serum transaminases should be \<= 5-fold the institutional upper limits.~11. Patients must not have any co-existing severe medical illnesses, such as unstable angina, uncontrolled diabetes mellitus, uncontrolled arrhythmia or uncontrolled infection.~12. Patients must be able to sign an informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemcitabine + Carboplatin (Type: EXPERIMENTAL): Gemcitabine 1000 mg/m2 IV for 30 minutes on days 1 and 8 of 21 day cycle. Maximum of 9 cycles.~Carboplatin AUC 5 IV for 1 hour on day 1 of 21 day cycle. Maximum of 9 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Activated Recombinant FVII in Spinal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Elective spinal fusion surgery.~Exclusion Criteria:~* History of thrombotic disorders (myocardial infarction, deep vein thrombosis, pulmonary embolism, stroke, disseminated intravascular coagulation or peripheral artery thrombosis)~* Any trauma within the last 3 months leading to hospitalization \> 24 hours~* Angina or known coronary artery disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with Type 2 Diabetes for at least three months prior to study~* Diabetes treated with metformin only~* Give consent and sign an informed consent form.~* Agree to follow specific requirements of birth control during participation.~Exclusion Criteria:~* Type I Diabetes.~* Treatment with insulin within 3 months prior to screening~* History of diabetic ketoacidosis or lactic acidosis~* Allergy or sensitivity to metformin or similar drugs or any medical conditions which prohibit metformin use~* Excessive blood donation 56 days before the start of the study~* Urinary tract or bladder infections within four weeks of study start~* Alcohol abuse or illicit drug use within 12 months of study start~* Receiving other investigational drugs or participating in other research trials within 30 of the study start~* Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements with 7-14 days of study start~* Live alone without regular, daily interactions with someone who can be an emergency contact

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Subjects receiving treatment P (Type: PLACEBO_COMPARATOR): Eligible subjects will receive placebo twice daily along with metformin twice daily for 13 days.
- Subjects receiving treatment A (Type: EXPERIMENTAL): Eligible subjects will receive GSK189075 500 milligrams twice daily along with metformin twice daily for 13 days.
- Subjects receiving treatment B (Type: EXPERIMENTAL): Eligible subjects will receive GSK189075 750 milligrams twice daily along with metformin twice daily for 13 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patient Inclusion Criteria:~* Male or female, aged 9 years and above~* Has facial non-nodular AV with IGA score of moderate or severe~* Considered as a potential candidate for sarecycline (Seysara®) treatment, per clinician judgment~Caregiver Inclusion Criteria:~* Primary caregiver of the study-eligible patient~* Male or female, aged 18 years and above~Exclusion Criteria:~* Patients with any known resistance to other tetracyclines~* Patients with any dermatological or physical condition of the face that could interfere with the AV clinical evaluations.~* Patients with any history of allergy to tetracycline-class antibiotics, pseudomembranous colitis or antibiotic-associated colitis.~* Unable to comply with the requirements of the study or patients who in the opinion of the Site Investigator should not participate in the study~Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sarecycline (Type: None): Eligible patients prescribed with commercially available sarecycline will be followed-up for 12 weeks post-initiation of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 6 and \< 18 years of age~* ≥ 18 kg (\~ 40 lbs.)~* TS diagnosis and both motor and vocal tics that cause impairment with normal routines~* Minimum score of 20 on the YGTSS-Total Tic Score~* May not be taking any medications used to treat motor or vocal tics for at least 14 days prior to Baseline.~* Effective contraception during the study and 30 days after last study dose for sexually active subjects~Exclusion Criteria:~* Certain mood or psychiatric disorders (i.e., dementia, bipolar disorder, schizophrenia, major depressive disorder)~* Unstable medical illness or clinically significant lab abnormalities~* Risk of suicide~* Pregnant or lactating women~* Moderate to severe renal insufficiency~* Hepatic insufficiency~* Positive urine drug screen~* Unstable doses for drugs to treat anxiety, depression, Attention Deficit Hyperactivity Disorder~* Certain medications that would lead to drug interactions~* Recent behavioral therapy

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Ecopipam HCI 2 mg/kg/day (Type: EXPERIMENTAL): Ecopipam HCl 12.5-, 50-, 75- and 100-mg tablets; 2 mg/kg/day target dose; oral administration daily in evenings
- Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo tablets taken orally in the evening

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HbA1c value between 7.5-9%~* Using multiple daily insulin injections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo injection will be supplied in the same 5-mL multidose glass vials with a rubber stopper.Ingredients: D-Mannitol 43.0 mg/mL Metacresol 2.25 mg/mL Glacial acetic acid 1.53 mg/mL Sodium acetate trihydrate 0.61 mg/mL pH 4.0 Water for injection qs to 5.0 mL
- Pramlintide Acetate (AC137) (Type: ACTIVE_COMPARATOR): Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide injection is 0.6 mg/mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Varicella-history positive, herpes zoster (HZ)-history negative patients~* 60 years of age and older receiving chronic/maintenance systemic corticosteroid therapy at a daily dose of 5 to 20 mg of prednisone or equivalent for at least the 2 weeks immediately prior to enrollment and expected to continue to receive a daily dose of 5 to 20 mg of prednisone or equivalent for the 6-week primary safety follow-up period (dose may vary within this range during the 6-week postvaccination period)~* All females enrolling must be postmenopausal~Exclusion Criteria:~* Patients with a history of hypersensitivity reaction to gelatin or neomycin~* Prior receipt of varicella or zoster vaccine; prior history of herpes zoster~* Immune globulin and/or blood products given within 5 months prior to or expected within the 6-week postvaccination period~* Receipt of any live virus vaccinations within 1 month or receipt of any inactivated vaccinations within 7 days prior to enrollment~* Known immune deficiency that is caused by a medical condition~* Any use in the 8 weeks prior to vaccination or for 6 weeks after vaccination other medications which may suppress the immune system including methotrexate, corticosteroids at a daily dose greater than 20 mg of prednisone or equivalent, agents used to treat cancer, or medications which alter the level of the immune response used to treat arthritis or other illnesses~* Concomitant use of antiviral therapy~* A history of alcohol abuse or recreational drug use

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ZOSTAVAX™ (Type: EXPERIMENTAL): Participants administered ZOSTAVAX™ on Day 1.
- Placebo (Type: PLACEBO_COMPARATOR): Participants administered Placebo on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete